Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease

Не применимо Завершено NCT03696797

Заболевание	Iron, Diabetes, Nonalcoholic Fatty Liver
Фаза	Не применимо
Спонсор	Wake Forest University Health Sciences
Статус	Завершено
Участники	132 участн.
Вмешательство	Blood Donation, Sham Blood Donation
Дата начала	3.05.2019
Дата завершения	3.01.2025
Публикация результатов	9.06.2026

Кратко

This is a treatment study to determine if reducing the body's iron stores by blood donation will improve diabetes control and other problems associated with diabetes such as fatty liver disease.

HgbA1c Value

Baseline · percentage of HgbA1c

Treatment Group	6.31 ± 0.75 percentage of HgbA1c
Control Group	6.22 ± 0.57 percentage of HgbA1c

HgbA1c Value

month 6 · percentage of HgbA1c

Treatment Group	6.43 ± 0.77 percentage of HgbA1c
Control Group	6.32 ± 0.56 percentage of HgbA1c

ALT (Alanine Aminotransferase) Value

Baseline · IU/L

Treatment Group	25.5 ± 15.7 IU/L
Control Group	24.1 ± 12.0 IU/L

Открыть в BENITIONS Открыть на ClinicalTrials.gov

Другие исследования по этому заболеванию

A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatoh — Akero Therapeutics, Inc
Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Va — Galectin Therapeutics Inc.
Effect of Obesity on Proton Pump Inhibitors — Children's Mercy Hospital Kansas City
Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatoti — Merck Sharp & Dohme LLC
Phase 2a Study of HPG1860 in Subjects With NASH — Hepagene (Shanghai) Co., Ltd.
Vitamin E Dosing Study — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Все исследования

Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.

English 한국어 日本語中文 Русский